Back to Interventions

Substance / Medication

Avatrombopag

SNOMED 770717002 UMLS C3886460

Overview

Active Ingredient

avatrombopag

RxNorm CUI

2045726

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Thrombocytopenic disorder

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

LOINC 718-7

secondary

LOINC 26464-8

secondary

LOINC 777-3

primary

Clinical Trials

3 trials linked to this intervention

3

Total Trials

1

Recruiting

1

With Results

Recent Trials

Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

NCT07133659Phase 4Recruiting25 enrolled

CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly

NCT05996393Phase 4Completed86 enrolled

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

NCT04638829Phase 4Completed60 enrolled

View all 3 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis.

Wojciechowski Piotr, Wilson Koo, Nazir Jameel et al. · Adv Ther · 2021

PMID: 33934279Meta-AnalysisFull text (PMC)

Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.

Armstrong Nigel, Büyükkaramikli Nasuh, Penton Hannah et al. · Health Technol Assess · 2020

PMID: 33108266Meta-AnalysisFull text (PMC)

Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Li Chunlu, Li Xiaoxuan, Huang Feihong et al. · Front Pharmacol · 2019

PMID: 31402863Meta-AnalysisFull text (PMC)

Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study.

Wang Leyu, Ye Lei, Zhao Xin et al. · Blood Cancer J · 2025

PMID: 40617806RCTFull text (PMC)

Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study.

Grace Rachael F, Leblebisatan Göksel, Aydinok Yesim et al. · Lancet Haematol · 2025

PMID: 40418942RCT

Recombinant Human Thrombopoietin Combined With Avatrombopag for Chemoradiotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma: A Prospective, Randomized Controlled Trial.

Jin Ting, Jin Qifeng, Hua Yonghong et al. · Br J Hosp Med (Lond) · 2025

PMID: 40994374RCT

A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP.

Tarantino Michael D, Bussel James B, Lee Eun-Ju et al. · Br J Haematol · 2023

PMID: 37339869RCT

Real-World Use of Avatrombopag in Children and Adolescents With Immune Thrombocytopenia.

Harris Emily M, Montcrieff Caitlin, O'Farrell Candelaria et al. · Pediatr Blood Cancer · 2026

PMID: 41214865Observational

Avatrombopag in adults with immune thrombocytopenia: A multicentre real-life observational study in Madrid, Spain (AVAMAD study).

Pascual-Izquierdo Cristina, Llacer-Ferrandis Mª Jose, de-la-Iglesia Almudena et al. · Br J Haematol · 2025

PMID: 39756394ObservationalFull text (PMC)

Long-term efficacy and safety of avatrombopag in Chinese children with primary immune thrombocytopenia: A real-world observational study.

Wang Nan, Wang Zhifa, Liu Jingjing et al. · Br J Haematol · 2025

PMID: 39756414Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

NUCC 207R00000X

Hematology (Internal Medicine) Physician

Internal Medicine — Hematology

NUCC 207RH0000X

Find a Provider

Health Goals

Goals connected through associated conditions

Optimize Iron and Blood Health

Quick Facts

Type: Substance / Medication
Fully Specified Name: Avatrombopag (substance)
SNOMED CT: 770717002
UMLS CUI: C3886460
RxNorm CUI: 2045726

Clinical Data

This intervention maps to 7 entities in the Healos knowledge graph.

1

Conditions

3

Biomarkers

2

Specialists

0

Symptoms

3

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.